Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday

Allarity Therapeutics (NASDAQ:ALLR) is expected to be posting its results before the market opens on Monday, March 30th. Analysts expect Allarity Therapeutics to post earnings of ($0.22) per share for the quarter.

Allarity Therapeutics Price Performance

ALLR stock opened at $1.08 on Monday. The business has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.24. The company has a market capitalization of $17.37 million, a P/E ratio of -1.83 and a beta of 0.20. Allarity Therapeutics has a 1-year low of $0.61 and a 1-year high of $2.35.

Institutional Trading of Allarity Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC acquired a new stake in shares of Allarity Therapeutics in the 3rd quarter worth $441,000. Renaissance Technologies LLC increased its position in Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock valued at $267,000 after buying an additional 181,426 shares in the last quarter. DRW Securities LLC purchased a new stake in Allarity Therapeutics in the fourth quarter valued at about $133,000. Citadel Advisors LLC purchased a new stake in Allarity Therapeutics in the third quarter valued at about $149,000. Finally, XTX Topco Ltd acquired a new stake in Allarity Therapeutics in the second quarter worth about $51,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets upped their price target on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.50.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.